Table 2.
Test positivity of DNA methylation biomarkers in Slovenian hrHPV‐positive clinician‐collected cervical scrapings
| A | In women ≥ 30 years (n = 235) | B | In women aged < 30 years (n = 18) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| controls | CIN 1 | CIN 2 | CIN 3 | cancer | p‐Trend | CIN 2+ | CIN 3+ | ||||||||
| Individual markers | |||||||||||||||
| ANKRD18CP 1 | 27% | (51/189) | 45% | (5/11) | 44% | (7/16) | 38% | (6/16) | 100% | (3/3) | 0.011 | 0% | (0/12) | 50% | (3/6) |
| C13orf18 | 4% | (8/189) | 9% | (1/11) | 13% | (2/16) | 25% | (4/16) | 67% | (2/3) | 6 × 10−60 | 0% | (0/12) | 17% | (1/6) |
| EPB41L3 1 | 31% | (59/189) | 36% | (4/11) | 56% | (9/16) | 81% | (13/16) | 100% | (3/3) | 2 × 10−60 | 17% | (2/12) | 50% | (3/6) |
| JAM3 | 6% | (11/189) | 9% | (1/11) | 25% | (4/16) | 63% | (10/16) | 100% | (3/3) | 6 × 10−15 | 8% | (1/12) | 50% | (3/6) |
| SOX1 1 | 13% | (24/189) | 27% | (3/11) | 44% | (7/16) | 69% | (11/16) | 100% | (3/3) | 1 × 10−11 | 17% | (2/12) | 50% | (3/6) |
| ZSCAN1 1 | 12% | (22/189) | 18% | (2/11) | 25% | (4/16) | 50% | (8/16) | 100% | (3/3) | 2 × 10−70 | 17% | (2/12) | 33% | (2/6) |
| Methylation marker panels | |||||||||||||||
| ANKRD18CP/C13orf18/JAM3 | 31% | (59/189) | 45% | (5/11) | 50% | (8/16) | 63% | (10/16) | 100% | (3/3) | 3 × 10−10 | 8% | (1/12) | 67% | (4/6) |
| C13orf18/EPB41L3/JAM3 1 | 34% | (64/189) | 36% | (4/11) | 63% | (10/16) | 94% | (15/16) | 100% | (3/3) | 7 × 10−14 | 17% | (2/12) | 67% | (4/6) |
| SOX1/ZSCAN1 1 , 2 | 16% | (30/189) | 27% | (3/11) | 44% | (7/16) | 75% | (12/16) | 100% | (3/3) | 5 × 10−11 | 17% | (2/12) | 50% | (3/6) |
1
Significantly different positivity in CIN2+ between age groups (p < 0.05).
2
Using a threshold for positivity at a methylation ratio of 19.1 for SOX1 or 132 for ZSCAN1 (see methods).